唾液腺癌放疗后疗效评估中18F-FDG PET/CT的多中心研究
该多中心回顾性研究纳入115例接受根治性或辅助放疗后行18F-FDG PET/CT的唾液腺癌患者,评估PET/CT在放疗后疗效评估中的价值。代谢完全缓解组5年局部区域控制率、无远处转移生存率、无进展生存率和总生存率均显著高于非完全缓解组(均P<0.001)。PET/CT预测局部区域复发的灵敏度63%、特异度91%、阴性预测值88%、准确率84%,在放疗前SUVmax≥7.39的肿瘤中灵敏度显著更高(88% vs 36%,P=0.011)。
要点
- 代谢完全缓解组5年局部区域控制率90% vs 非完全缓解组43%,均P<0.001
- PET/CT预测局部区域复发灵敏度63%、特异度91%、阴性预测值88%、准确率84%
- 放疗前SUVmax≥7.39者灵敏度88% vs <7.39者36%,P=0.011
核心结论
- 放疗后18F-FDG PET/CT具有高阴性预测值和特异度,代谢完全缓解预示良好结局。
- 对高SUVmax的唾液腺癌灵敏度更高,有助于早期发现存活肿瘤。
研究设计与样本
- 多中心回顾性研究,回顾性分析2004年至2021年间115例接受根治性或辅助放疗后行18F-FDG PET/CT的唾液腺癌患者。
- 大多数为腮腺恶性肿瘤(50%),最常见组织学亚型为腺样囊性癌(29%)和黏液表皮样癌(18%)。
主要发现
- 中位随访65个月,放疗后解剖影像(CT/MRI)显示51例(44%)完全缓解。
- 53例部分缓解或疾病稳定患者中仅17例(32%)出现局部区域复发,5年局部区域控制率69%。
- 放疗后18F-FDG PET/CT显示81例(70%)代谢完全缓解;代谢完全缓解组5年局部区域控制率90% vs 非完全缓解组43%,无远处转移生存率80% vs 48%,无进展生存率76% vs 24%,总生存率89% vs 42%(均P<0.001),单因素和多因素分析均证实。
- PET/CT发现18例(16%)额外存活肿瘤,促使7例(6%)接受挽救性局部治疗。
- 预测局部区域复发的灵敏度63%、特异度91%、阳性预测值70%、阴性预测值88%、准确率84%;放疗前SUVmax≥7.39的肿瘤灵敏度88% vs SUVmax<7.39者36%(P=0.011)。
关键数值与推荐
- 代谢完全缓解定义为放疗后18F-FDG PET/CT未见异常代谢灶,共81例(70%)。
- 放疗前SUVmax≥7.39为灵敏度亚组分析阈值。
临床怎么用
- 原文结论认为放疗后18F-FDG PET/CT具有高阴性预测值和特异度,代谢完全缓解预示良好结局,对高SUVmax唾液腺癌灵敏度更高,有助于早期发现存活肿瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This multicenter study investigates the efficacy of 18 F-FDG PET/CT in postradiotherapy (post-RT) response evaluation in salivary gland carcinoma (SGC). METHODS: We retrospectively reviewed 115 SGC patients who underwent definitive or adjuvant RT followed by 18 F-FDG PET/CT between 2004 and 2021. Most tumors were parotid gland malignancies (50%). The most common histological subtypes were adenoid cystic (29%) and mucoepidermoid carcinomas (18%). RESULTS: The median follow-up was 65 months. Post-RT anatomic images (CT/MRI) revealed complete response (CR) in 51 patients (44%). Among 53 patients with partial response or stable disease, only 17 (32%) patients experienced locoregional recurrence, with a 5-year locoregional control rate of 69%. Post-RT 18 F-FDG PET/CT documented metabolic CR in 81 patients (70%). Metabolic complete responders had significantly higher 5-year locoregional control (90% vs 43%), distant metastasis-free survival (80% vs 48%), progression-free survival (76% vs 24%), and overall survival rates (89% vs 42%) compared with non-complete responders (all P < 0.001), as confirmed in both univariate and multivariate analyses. It identified additional viable tumors in 18 cases (16%) and facilitated salvage local therapies in 7 patients (6%). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of post-RT 18 F-FDG PET/CT were 63%, 91%, 70%, 88%, and 84%, respectively, in predicting locoregional recurrence. 18 F-FDG PET/CT showed significantly higher sensitivity (88% vs 36%, P = 0.011) in tumors with pre-RT SUV max ≥7.39 compared with those with SUV max <7.39. CONCLUSIONS: Post-RT 18 F-FDG PET/CT demonstrates high negative predictive value and specificity, with metabolic CR predicting excellent outcomes. Additionally, it exhibits higher sensitivity for high-SUV max SGC, facilitating early detection of viable tumors.
引用
- Chen PY, Cheng NM, Lin CY, et al. Postradiotherapy Response Assessment Using 18 F-FDG PET/CT in Salivary Gland Carcinoma-A Multicenter Study. Clin Nucl Med. 2024. PMID: 39479972. doi:10.1097/RLU.0000000000005538
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。